Dear Editor, The pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) highlights the need to develop effective …

Novel COVID-19 therapeutics are urgently needed. We generated a phage-displayed
human antibody V H domain library from which we identified a high-affinity V H binder ab8. …

The COVID‐19 pathogen, SARS‐CoV‐2, requires its main protease (SC2M Pro ) to digest
two of its translated long polypeptides to form a number of mature proteins that are essential …

Guided by a computational docking analysis, about 30 Food and Drug Administration/European
Medicines Agency (FDA/EMA)-approved small-molecule medicines were characterized …

Host-cell cysteine proteases play an essential role in the processing of the viral spike protein
of SARS coronaviruses. K777, an irreversible, covalent inactivator of cysteine proteases …

Effective therapies are urgently needed for the SARS-CoV-2/COVID-19 pandemic. We identified
panels of fully human monoclonal antibodies (mAbs) from large phage-displayed Fab, …

Cathepsin L is a key host cysteine protease utilized by coronaviruses for cell entry and is a
promising drug target for novel antivirals against SARS-CoV-2. The marine natural product …

The key to battling the COVID-19 pandemic and its potential aftermath is to develop a variety
of vaccines that are efficacious and safe, elicit lasting immunity, and cover a range of SARS-…

SARS-CoV-2 uses human angiotensin-converting enzyme 2 (ACE2) as the primary receptor
to enter host cells and initiate the infection. The critical binding region of ACE2 is an ∼30-…

A “universal” platform that can rapidly generate multiplex vaccine candidates is critically
needed to control pandemics. Using the severe acute respiratory syndrome coronavirus 2 as a …